the group consisting of oligonucleotides, polymers as artificial antibodies, and phage display binding sites; and

b. detecting the presence of human iNOS protein in said sample, said specific binding entity recognizing a region of human iNOS protein.

24. The method of claim 22 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTOD SEQ ID NO 32, SPVTQDDLQYHNLSKQQN SEQ ID NO 26, NNNVEKAPCATSSPVTQD and SPVTQDDLQYHNLSKQQN SEQ ID NO 29, PALVQGILERVVDGPTPH SEQ ID NO 30, GIVPFRSFWQQRLHDSQH SEQ ID NO 25, and RMTLVFGCRRPDEDHITQ SEQ ID NO 31.

25. The method of claim 23 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTOD SEQ ID NO 32, SPVTQDDLQYHNLSKQQN SEQ ID NO 26, NNNVEKAPCATSSPVTQD and SPVTQDDLQYHNLSKQQN SEQ ID NO 29, PALVQGILERVVDGPTPH SEQ ID NO 30, GIVPFRSFWQQRLHDSQH SEQ ID NO 25, and RMTLVFGCRRPDEDHITQ SEQ ID NO 31.

26. The method of claim 22 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

27. The method of claim 22 in which said step of the presence of human iNOS protein comprises a qualitative analysis.

28. The method of claim 22 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

29 30. An immunoassay method for a sample comprising the steps of:

Rule 1.126

a. contacting the sample with a specific binding entity reactive to mimics of human iNOS protein;

b. revealing the presence of human iNOS protein in said sample, said specific binding entity being reactive to mimics of a region of human iNOS protein.

30 29
31. The method of claim 30 in which said specific binding entity is selected from the group consisting of: peptides, recombinant peptides, fusion proteins, fusion peptides, phage displayed proteins, phage displayed peptides, peptide libraries, and peptide analogue libraries.

31 30
32. The method of claim 31 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTOD SEQ ID NO 32, SPVTQDDLQYHNLSKQQN SEQ ID NO 26, NNNVEKAPCATSSPVTQD and SPVTQDDLQYHNLSKQQN SEQ ID NO 29, PALVQGILERVVDGPTPH SEQ ID NO 30, GIVPFRSFWQQRLHDSQH SEQ ID NO 25, and RMTLVFGCRRPDEDHITQ SEQ ID NO 31.

32 29
33. The method of claim 30 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

33 29
34. The method of claim 30 in which said immunoassay is a clinical diagnostic assay.

34 29
35. The method of claim 30 in which said step of revealing the presence of human iNOS protein is a qualitative analysis.

35 29
36. The method of claim 30 in which said step of revealing the presence of human iNOS is a quantitative analysis.

36 29
~~37~~. The method of claim ~~30~~ in which said specific binding entity is any one of the peptide analogues of Table VII.

1.126

37 29
~~38~~. The method of claim ~~30~~ in which said specific binding entity is any one of the peptide analogues of Table IX.

1.126

36 29
~~39~~. The assay of claim ~~30~~ which is of the type selected from the group consisting of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture, and RIA.

1.126

39
~~40~~. The assay of claim 22 which is of the type selected from the group consisting of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture, and RIA.

1.126

40 36
~~41~~. The method of claim ~~37~~ in which said specific binding entity is a peptide analogue having the sequence: VTQDDLQ SEQ ID NO 89.

1.126

41 37
~~42~~. The method of claim ~~38~~ in which said specific binding entity is a peptide analogue having the sequence: VQGILERV SEQ ID NO 121.

1.126

R E M A R K S

The above amendment is filed in response to the Examiner's Action, paper number 25. In that Action, the Examiner requested a substitute specification be submitted. A substitute specification is enclosed with this response.

Sequence listings have been added to newly submitted claims in accordance with the Examiner's request with respect to original claims 3 and 10.